The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IMV | +9,900% | -100% | -92.07% | -100% |
| S&P | +19.89% | +109.18% | +15.89% | +419% |
IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.
Currently no data to display
Currently no data to display.
Currently no data to display.
| Metric | YoY Change |
|---|
IMV earnings call for the period ending June 30, 2021.
IMV earnings call for the period ending March 31, 2021.
IMV earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
